Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(22 sites)
United States
UC Denver Hemoph & Thrombo Ctr, Aurora, Colorado Indiana Hemophilia-Thromb Ctr, Indianapolis, Indiana University of Iowa_Iowa City, Iowa City, Iowa Penn State MS Hershey Med Ctr, Hershey, Pennsylvania St Christopher Hosp for Child, Philadelphia, Pennsylvania Austria
Universitätsklinik für Innere Medizin V, Innsbruck AKH - Klin. Abt. f. Haematologie u. Haemostaseologie, Vienna Germany
Vivantes Netzwerk für Gesundheit GmbH - Vivantes Klinikum im Friedrichshain, Berlin Universitätsklinikum Bonn - Institut für Experimentelle Hämatologie, Bonn Medizinische Hochschule Hannover - Hämatologie, Hämostaseologie, Onkologie, Hanover Italy
AOU Careggi Firenze, Florence Azienda Ospedaliera Universitaria Federico II di Napoli, Naples Poland
Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok Uniwersyteckie Centrum Kliniczne, Gdansk Instytut Hematologii i Transfuzjologii, Warsaw Spain
Hospital Vall d'Hebron, Barcelona Hospital Universitario La Paz, Madrid Hospital Regional Universitario de Málaga, Málaga Hospital Clinico Universitario de Salamanca, Salamanca United Kingdom
Queen Elizabeth Hospital, Birmingham - Haemophilia, Birmingham Royal Free Hospital - Haemophilia, London Royal Hallamshire Hospital, Sheffield